Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In The News: Government Officials Go Private; New Top Leadership At Advaxis, Aerie

Executive Summary

Former FDA CIO Perakslis joins IT consultancy; Former DoJ FCA litigator May joins Arnold & Porter; PatientsLikeMe names researchers to pilot test new PRO validation tool; more personnel announcements in this month’s column.

You may also be interested in...

With Shire Behind Him, Jonas Starts New Chapter At SAGE

The upbeat ex-Shire exec has moved on from his tumultuous break-up with the specialty pharma and is on day three in his new role as CEO of CNS start-up SAGE Therapeutics. He will focus on bringing CNS products forward for orphan indications.

It Takes Two: FDA Reorganizes Office Of Information Management

Taha Kass-Hout has begun his tenure as Chief Informatics Officer, focusing on scientific computing; the agency expects to hire a Chief Information Officer within 60 to 90 days to handle software development and deployment and infrastructure.

PatientsLikeMe Developing Platform To Validate Patient-Reported Outcomes

While the primary objective will be to help members of the online patient community better manage their health, the new platform will offer an opportunity for pharmaceutical companies to validate patient-reported outcomes that they develop, something that could be useful as PROs gain more traction in the FDA review process.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts